Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) to Ring The Nasdaq Stock Market Closing Bell
January 04 2018 - 4:30PM
What: Rocket Pharmaceuticals, Inc.
(Nasdaq:RCKT), a leading U.S.-based multi-platform gene therapy
company, will visit the Nasdaq MarketSite in Times Square.
In honor of the occasion, Gaurav Shah, MD, Chief
Executive Officer, will ring the Closing Bell.
Where:Nasdaq MarketSite – 4 Times Square – 43rd
& Broadway – Broadcast Studio
When:Friday, January 5, 2018 – 3:45 p.m. to
4:00 p.m. ET
Rocket Pharmaceuticals Contact:Claudine Prowse,
PhDcp@rocketpharma.com
Nasdaq MarketSite Media Contact:Emily Pan(646)
441-5120emily.pan@nasdaq.com
Feed Information:Fiber Line (Encompass
Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC
3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Social Media:For multimedia features such as
exclusive content, photo postings, status updates and video of bell
ceremonies, please visit our Facebook
page:http://www.facebook.com/NASDAQ.
For photos from ceremonies and events, please visit our
Instagram page:http://instagram.com/nasdaq
For livestream of ceremonies and events, please visit our
YouTube page:http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter
page:http://twitter.com/nasdaq
For exciting viral content and ceremony photos, please visit our
Tumblr page:http://nasdaq.tumblr.com/
Webcast: A live stream of the Nasdaq Closing
Bell will be available at: https://new.livestream.com/nasdaq/live
or http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos: To obtain a hi-resolution photograph of
the Market Close, please go to
http://business.nasdaq.com/discover/market-bell-ceremonies and
click on the market close of your choice.
About Rocket Pharmaceuticals, Inc.Rocket
Pharmaceuticals, Inc. (NASDAQ:RCKT) (“Rocket”) is an emerging,
clinical-stage biotechnology company focused on developing
first-in-class gene therapy treatment options for rare,
undertreated diseases. Rocket’s multi-platform development approach
applies the well-established lentiviral vector (LVV) and
adeno-associated viral vector (AAV) gene therapy platforms.
Rocket's lead clinical program is a LVV-based gene therapy for the
treatment of Fanconi Anemia (FA), a difficult to treat genetic
disease that leads to bone marrow failure and potentially cancer.
Preclinical studies of additional bone marrow-derived disorders are
ongoing and target Pyruvate Kinase Deficiency (PKD), Leukocyte
Adhesion Deficiency-I (LAD-I) and Infantile Malignant Osteopetrosis
(IMO). Rocket is also developing an AAV-based gene therapy program
for an undisclosed rare pediatric disease. For more information
about Rocket, please visit www.rocketpharma.com.
About Nasdaq:Nasdaq (Nasdaq:NDAQ) is a leading
global provider of trading, clearing, exchange technology, listing,
information and public company services. Through its diverse
portfolio of solutions, Nasdaq enables customers to plan, optimize
and execute their business vision with confidence, using proven
technologies that provide transparency and insight for navigating
today's global capital markets. As the creator of the world's first
electronic stock market, its technology powers more than 90
marketplaces in 50 countries, and 1 in 10 of the world's securities
transactions. Nasdaq is home to approximately 3,900 total listings
with a market value of approximately $12 trillion. To learn more,
visit: http://business.nasdaq.com
-NDAQA-
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Apr 2023 to Apr 2024
